The company has entered into a binding term sheet with Stelis to acquire its Bengaluru-based Unit 3 biologics manufacturing unit, Syngene said in a late night statement on Tuesday. Stelis ...
Strides Pharma Science has agreed to sell the biologics Unit-3 manufacturing facility of its associate company Stelis Biopharma to Syngene International for INR702 crore ($94m) in cash.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback